Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study

This is the authors' abstract. We don't add key points for this paper.

We present data from the TRuE-V1/TRuE-V2 rollover TRuE-V long-term extension study evaluating withdrawal and continuation of ruxolitinib cream treatment. Among patients with near-complete facial repigmentation in TRuE-V1/TRuE-V2, approximately 70% of those randomized to treatment continuation and approximately 40% of those randomized to treatment withdrawal maintained facial repigmentation indicative of treatment success (i.e. ≥ F-VASI 75). Lost repigmentation could be regained in a timely manner following reinitiation of open-label active treatment.